Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,231 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,680 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01361711 | Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia | active not recruiting | Phase 2 | 53 | Northwestern UniversityOTHER | 2 | May 23, 2025 | clinicaltrials |
| NCT06552572 | Glofitamab in Relapsed or Refractory Diffuse Large B-cell Lymphoma After CD19 Chimeric Antigen Receptor T-cell Therapy(Glory) | active not recruiting | Phase 2 | 30 | Samsung Medical CenterOTHER | 1 | May 21, 2025 |
| clinicaltrials |
| NCT04730258 | A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML(TWT-202) | active not recruiting | Phase 1 / Phase 2 | 72 | Treadwell Therapeutics, IncINDUSTRY | 3 | May 18, 2025 | clinicaltrials |
| NCT05299164 | GVM±R in Patients With Relapsed or Refractory Aggressive NHL | active not recruiting | Phase 1 | 18 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT04202835 | ATG Plus PTCy vs ATG for CGVHD Prophylaxis | active not recruiting | Phase 2 | 80 | McMaster UniversityOTHER | 2 | May 11, 2025 | clinicaltrials |
| NCT03168815 | Low-Flow vs. High-Flow Nasal Cannula for Hypoxemic Immunocompromised Patients During Diagnostic Bronchoscopy | active not recruiting | N/A | 98 | Mount Sinai Hospital, CanadaOTHER | 1 | May 9, 2025 | clinicaltrials |
| NCT05179824 | Tempus Priority Study: A Pan-tumor Observational Study | active not recruiting | — | 1,000 | Tempus AIINDUSTRY | 1 | May 6, 2025 | clinicaltrials |
| NCT04460248 | Zanubrutinib, Lenalidomide and Rituximab (ZR2) in Elderly Treatment-naive Patients With Diffuse Large B-cell Lymphoma (DLBCL) | active not recruiting | Phase 2 | 40 | Ruijin HospitalOTHER | 1 | May 2, 2025 | clinicaltrials |
| NCT01761968 | Long-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative Neoplasms | active not recruiting | Phase 2 | 90 | ItalfarmacoINDUSTRY | 3 | Apr 30, 2025 | clinicaltrials |
| NCT03756896 | Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With High-Risk Multiple Myeloma | active not recruiting | Phase 2 | 29 | Emory UniversityOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| NCT04232241 | Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia | active not recruiting | Phase 2 | 167 | Universitätsklinikum Hamburg-EppendorfOTHER | 7 | Apr 22, 2025 | clinicaltrials |
| NCT03952078 | A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma | active not recruiting | Phase 1 | 151 | Corvus Pharmaceuticals, Inc.INDUSTRY | 4 | Apr 16, 2025 | clinicaltrials |
| NCT02735083 | A Study to Evaluate the Long-term Safety of Patients With Advanced Lymphoid Leukemia Who Have Been Previously Administered With UCART19 | active not recruiting | Phase 1 | 28 | Institut de Recherches Internationales ServierOTHER | 5 | Apr 11, 2025 | clinicaltrials |
| NCT06924424 | Aponermin, Pomalidomide, Dexamethasone for Patients With Relapsed/ Refractory Multiple Myeloma | active not recruiting | N/A | 105 | Peking University People's HospitalOTHER | 1 | Apr 11, 2025 | clinicaltrials |
| NCT03600441 | Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma(FORERUNNER) | active not recruiting | Phase 2 | 139 | Xynomic Pharmaceuticals, Inc.INDUSTRY | 3 | Apr 10, 2025 | clinicaltrials |
| NCT03934567 | A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma | active not recruiting | Phase 2 | 87 | Xynomic Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 10, 2025 | clinicaltrials |
| NCT04024696 | A Clinical Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Abexinostat in Chinese Patients | active not recruiting | Phase 1 / Phase 2 | 12 | Xynomic Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 10, 2025 | clinicaltrials |
| NCT04891809 | Isatuximab in Combination With Rd Compared to Rd in Elderly Patients (Aged ≥70 Years) With NDMM | active not recruiting | Phase 2 | 198 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 3 | Apr 10, 2025 | clinicaltrials |
| NCT06918080 | Hepatoprotective Measures for Children at High Risk of NAFLD | active not recruiting | Phase 4 | 200 | Ain Shams UniversityOTHER | 1 | Apr 9, 2025 | clinicaltrials |
| NCT04233346 | The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation | active not recruiting | Phase 2 | 93 | Otsuka Beijing Research InstituteINDUSTRY | 1 | Apr 4, 2025 | clinicaltrials |
| NCT06065007 | Quality of Life and Disease-related Symptoms in Individuals With Systemic Mastocytosis | active not recruiting | — | 400 | Uppsala UniversityOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT03376672 | Ixazomib Plus Lenalidomide Plus Dexamethasone for Newly Diagnosed Myeloma Patients | active not recruiting | Phase 2 | 120 | Raija SilvennoinenOTHER | 4 | Apr 3, 2025 | clinicaltrials |
| NCT03480334 | Abscopal Effect of Radiotherapy and Nivolumab in Relapsed Hodgkin Lymphoma After Anti-PD1 Therapy(AERN) | active not recruiting | Phase 2 | 26 | University of CologneOTHER | 1 | Apr 3, 2025 | clinicaltrials |
| NCT03918655 | MIF Involvement in AML(MIFAML) | active not recruiting | — | 186 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Apr 2, 2025 | clinicaltrials |
| NCT04392037 | Iberdomide Combined With Low-dose Cyclophosphamide and Dexamethasone(ICON) | active not recruiting | Phase 2 | 60 | Amsterdam UMC, location VUmcOTHER | 1 | Mar 28, 2025 | clinicaltrials |
| NCT04962126 | Frontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and Without RadiOtherapy(FLUORO) | active not recruiting | Phase 2 | 15 | Olivia Newton-John Cancer Research InstituteOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT05883956 | A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia(PREFER-HMA) | active not recruiting | Phase 3 | 13 | Otsuka Australia Pharmaceutical Pty LtdINDUSTRY | 2 | Mar 20, 2025 | clinicaltrials |
| NCT06396611 | Exercise As Intervention in Chronic Lymphocytic Leukemia(ADRENALINE) | active not recruiting | N/A | 11 | Universidade do PortoOTHER | 1 | Mar 19, 2025 | clinicaltrials |
| NCT03496402 | Biological Characterisation of High Risk CHildhood Cancer in Children, Adolescents and Young Adults (MICCHADO)(MICCHADO) | active not recruiting | N/A | 600 | Institut CurieOTHER | 1 | Mar 18, 2025 | clinicaltrials |
| NCT04717700 | Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients(SABLe) | active not recruiting | Phase 2 | 50 | Ida Bruun KristensenOTHER | 3 | Mar 18, 2025 | clinicaltrials |
| NCT04980885 | A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia | active not recruiting | Phase 1 / Phase 2 | 68 | AkesoINDUSTRY | 1 | Mar 3, 2025 | clinicaltrials |
| NCT04072458 | A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies | active not recruiting | Phase 1 | 30 | Bio-Path Holdings, Inc.INDUSTRY | 1 | Feb 24, 2025 | clinicaltrials |
| NCT05434312 | TGRX-678 Chinese Phase I in Chronic Myelogenous Leukemia (CML) Patients | active not recruiting | Phase 1 | 90 | Shenzhen TargetRx Co., Ltd.INDUSTRY | 1 | Feb 24, 2025 | clinicaltrials |
| NCT03618485 | Registry of Patients With MPNs in Taiwan | active not recruiting | — | 500 | Chang Gung Memorial HospitalOTHER | 1 | Feb 14, 2025 | clinicaltrials |
| NCT04041050 | A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm | active not recruiting | Phase 1 | 85 | AbbVieINDUSTRY | 14 | Feb 14, 2025 | clinicaltrials |
| NCT06093841 | Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL | active not recruiting | Phase 2 | 46 | Shanghai Ming Ju Biotechnology Co., Ltd.INDUSTRY | 1 | Feb 11, 2025 | clinicaltrials |
| NCT06452446 | Telehealth-based Symptom Management for Veterans Treated With Selinexor(Selinexor) | active not recruiting | — | 20 | Durham VA Medical CenterFED | 1 | Feb 10, 2025 | clinicaltrials |
| NCT03283137 | Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL | active not recruiting | Phase 1 | 20 | University of ChicagoOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT06386861 | Validating the Spanish "Attitudes Toward Genomics and Precision Medicine" (AGPM). | active not recruiting | N/A | 851 | Boston CollegeOTHER | 1 | Feb 5, 2025 | clinicaltrials |
| NCT03212404 | Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers | active not recruiting | Phase 1 | 272 | Checkpoint Therapeutics, Inc.INDUSTRY | 9 | Feb 3, 2025 | clinicaltrials |
| NCT06734078 | An Italian Multicenter Retrospective Observational Study to Assess the Clinical Characteristics and the Outcome of Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin Plus Rituximab (± Bendamustine) Under Named Patient Programme(POSS) | active not recruiting | — | 100 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT06798805 | Unraveling the Role of Extracellular Vesicles-driven Senescence in Myeloproliferative Neoplasms | active not recruiting | — | 110 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT04722848 | Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL | active not recruiting | Phase 3 | 236 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Jan 23, 2025 | clinicaltrials |
| NCT04782687 | Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma | active not recruiting | Phase 2 | 73 | US Oncology ResearchINDUSTRY | 1 | Jan 16, 2025 | clinicaltrials |
| NCT05263583 | Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma | active not recruiting | Phase 2 | 14 | Cothera Bioscience, IncINDUSTRY | 2 | Jan 14, 2025 | clinicaltrials |
| NCT05885464 | A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL) | active not recruiting | Phase 1 / Phase 2 | 5 | Beam Therapeutics Inc.INDUSTRY | 1 | Jan 13, 2025 | clinicaltrials |
| NCT04786028 | A Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in ND-TEMM | active not recruiting | Phase 2 | 72 | Canadian Myeloma Research GroupOTHER | 1 | Jan 8, 2025 | clinicaltrials |
| NCT06764589 | Liquid Micro-biopsy: a Novel Approach to Study Tumor Microenvironment From the Peripheral Blood | active not recruiting | — | 90 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 8, 2025 | clinicaltrials |
| NCT05838131 | Study of CT071 Injection in RRMM or PPCL | active not recruiting | Early Phase 1 | 20 | Shanghai Changzheng HospitalOTHER | 1 | Jan 7, 2025 | clinicaltrials |
| NCT06760936 | Pixantrone as Bridging Therapy to Allogenic Transplant or CAR-T Cell Therapy in DLBCL Patients(PIXBRIDGE) | active not recruiting | — | 15 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 7, 2025 | clinicaltrials |
Data updated 23 days agoSource updated May 23, 2025source: clinicaltrials